查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2020220

結核病診斷市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類的洞察，2026-2034 年預測

Tuberculosis Diagnostics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 121 Pages | 商品交期: 請詢問到貨日

價格

結核病診斷市場成長要素

全球結核病（TB）診斷市場預計在2025年達到24億美元，2026年成長至25.3億美元，並在2034年達到41.4億美元，預測期內複合年成長率（CAGR）為6.33%。 2025年，北美將以28.34%的市佔率領先，這主要得益於其先進的醫療基礎設施、完善的疾病監測系統以及眾多大型診斷公司的存在。

結核病是由結核分枝桿菌引起的高度傳染性感染疾病，主要侵襲肺部，但也可能影響其他器官，例如大腦和脊髓。早期準確診斷對於預防感染傳播至關重要，這顯著增加了全球對先進結核病診斷解決方案的需求。

市場趨勢

擴大公私合營

公私合營是結核病診斷市場的一大趨勢。政府和私營機構正攜手合作，以提高診斷服務的可近性和效率。例如，在印度等國家，國家結核病控制項目下的合作顯著加強了診斷基礎設施。此外，羅氏診斷公司於2023年與美國疾病管制與預防中心（CDC）建立的夥伴關係，也有助於提高結核病重災區的偵測能力。

向快速分子診斷過渡

快速分子診斷技術的日益普及正在改變結核病的檢測方式。這些檢測方法比傳統方法更快、更準確，有助於早期診斷並更好地進行疾病管理。包括基於次世代定序（NGS）的解決方案在內的持續產品創新，正在進一步加速這一趨勢。

市場成長要素

全球結核病發生率正在上升。

結核病發生率的上升是市場成長的主要促進因素。根據全球衛生統計數據，2021年約有1,060萬人被診斷出患有結核病，與往年相比顯著增加。在印度、中國和非洲部分地區等高發病率國家，病例數量不斷增加，推動了對診斷解決方案的需求。

政府的有利舉措

旨在根除結核病的政府項目和政策對市場擴張起到了顯著作用。例如，印度的「總理無結核病印度運動」（Pradhan Mantri TB Mukt Bharat Abhiyaan）以及結核病控制計畫醫療費用支出的增加，正在加速診斷技術的普及。以印度為例，2019年至2020年間，其在結核病根除項目上的支出約為3.997億美元。

提高公眾意識和篩檢計劃

大眾對結核病的認知不斷提高，篩檢範圍不斷擴大，從而提高了診斷率。各國政府和醫療機構正致力於早期發現，以防止疾病傳播，這推動了市場成長。

抑制因子

診斷方法的技術局限性

儘管診斷技術取得了進展，但某些診斷技術仍有其限制。傳統的痰液塗片顯微鏡檢查等方法靈敏度較低，且容易產生假陽性結果，尤其是在脆弱的組織層。而像GeneXpert這樣的先進方法需要穩定的電源，且試劑盒的保存期限有限，這給資源匱乏的環境帶來了挑戰。

市場區隔

按類型

市場細分包括基於培養的診斷方法、痰液塗片顯微鏡檢查、快速分子診斷等。預計到2026年，快速分子診斷將引領市場，佔50.60%的市場佔有率，主要得益於其高準確率、快速出結果以及不斷湧現的新產品。基於培養的診斷方法和顯微鏡檢查仍然發揮著重要作用，尤其是在對成本較為敏感的地區。

最終用戶

市場分為診斷檢查室和醫院兩大類。預計到2026年，診斷檢查室將佔67.61%的主導市場佔有率，這主要得益於檢查室設施的普及和對實驗室結核病檢測日益成長的依賴。由於醫院進行的診斷程序數量龐大，預計醫院也將顯著成長。

區域趨勢

北美：

預計該地區2025年市場規模將達6.8億美元，2026年將達7.1億美元。憑藉其強大的醫療保健基礎設施和較高的診斷技術普及率，該地區有望保持主導地位。

歐洲：

2025 年市場規模為 4.3 億美元，但在政府舉措和先進診斷技術的引入的支持下，預計 2026 年將成長至 4.5 億美元。

亞太地區：

它是規模最大、成長最快的地區，預計到 2025 年將達到 7.8 億美元，到 2026 年將達到 8.3 億美元。結核病高發病率和醫療基礎設施的改善是成長要素。

拉丁美洲、中東和非洲：

預計到2025年，拉丁美洲的醫療市場規模將達到2.4億美元，中東和非洲將達到2.8億美元。由於醫療保健投資的增加以及全球企業進入這些市場，預計將穩定成長。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 主要行業趨勢
  • 主要國家結核病發生率
  • 新冠疫情對市場的影響

第5章：2021-2034年全球結核病診斷市場分析、洞察與預測

  • 市場分析、洞察與預測：按類型
    • 基於培養方法的診斷
    • 痰液塗片顯微鏡檢查
    • 快速分子診斷
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 診斷檢查室
    • 醫院
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美結核病診斷市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲結核病診斷市場分析、洞察與預測（2021-2034年）

  • 國家
    • 德國
    • 法國
    • 英國
    • 義大利
    • 俄羅斯
    • 北歐的
    • 其他歐洲國家

第8章：亞太地區結核病診斷市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲結核病診斷市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲結核病診斷市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2026 年）
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • bioMerieux SA
    • QIAGEN
    • BD
    • Cepheid（Danaher）
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • Hologic, Inc.
    • Hain Lifescience GmbH
    • Oxford Immunotec USA, Inc.
Product Code: FBI102009

Growth Factors of tuberculosis (TB) diagnostics Market

The global tuberculosis (TB) diagnostics market was valued at USD 2.40 billion in 2025 and is projected to grow to USD 2.53 billion in 2026, reaching USD 4.14 billion by 2034, registering a CAGR of 6.33% during the forecast period. North America dominated the market in 2025 with a 28.34% share, driven by advanced healthcare infrastructure, strong disease surveillance systems, and the presence of major diagnostic companies.

Tuberculosis is a highly contagious infectious disease caused by Mycobacterium tuberculosis, primarily affecting the lungs but also capable of impacting other organs such as the brain and spine. Early and accurate diagnosis is crucial for controlling disease transmission, which has significantly increased the demand for advanced TB diagnostic solutions worldwide.

Market Trends

Rise in Public-Private Partnerships

Public-private partnerships have become a major trend in the TB diagnostics market. Governments and private organizations are collaborating to improve diagnostic accessibility and efficiency. For instance, collaborations under national TB programs in countries like India have significantly strengthened diagnostic infrastructure. Additionally, partnerships such as Roche Diagnostics' collaboration with the U.S. CDC in 2023 are enhancing laboratory capacities in high-burden regions.

Shift Toward Rapid Molecular Diagnostics

The increasing adoption of rapid molecular diagnostic technologies is transforming TB detection. These tests provide faster and more accurate results compared to traditional methods, supporting early diagnosis and better disease management. Continuous product innovations, including next-generation sequencing (NGS)-based solutions, are further accelerating this trend.

Market Growth Drivers

Increasing TB Incidence Globally

The rising prevalence of tuberculosis is a major factor driving market growth. According to global health estimates, approximately 10.6 million people were diagnosed with TB in 2021, reflecting a notable increase compared to previous years. High-burden countries such as India, China, and parts of Africa are witnessing growing patient populations, boosting demand for diagnostic solutions.

Favorable Government Initiatives

Government programs and policies aimed at eliminating TB are significantly contributing to market expansion. Initiatives such as India's Pradhan Mantri TB Mukt Bharat Abhiyaan and increased healthcare expenditure for TB control programs are enhancing diagnostic adoption. For example, India spent nearly USD 399.7 million on TB elimination programs in 2019-2020.

Growing Awareness and Screening Programs

Rising awareness about TB and increasing screening initiatives have led to higher diagnostic rates. Governments and healthcare organizations are focusing on early detection to reduce disease transmission, thereby supporting market growth.

Restraining Factors

Technical Limitations of Diagnostic Methods

Despite advancements, certain diagnostic techniques face limitations. Traditional methods like sputum smear microscopy have low sensitivity and may produce false-positive results, particularly in vulnerable populations. Advanced methods such as GeneXpert require stable electricity and have limited cartridge shelf life, posing challenges in low-resource settings.

Market Segmentation

By Type

The market is segmented into culture-based diagnostics, sputum smear microscopy, rapid molecular diagnostics, and others. The rapid molecular diagnostics segment dominated with a 50.60% share in 2026, driven by high accuracy, faster results, and increasing product launches. Culture-based diagnostics and microscopy continue to play a significant role, especially in cost-sensitive regions.

By End-user

The market is divided into diagnostic laboratories and hospitals. The diagnostic laboratories segment held a dominant share of 67.61% in 2026, attributed to the widespread availability of laboratory facilities and increasing reliance on lab-based TB testing. Hospitals are also expected to grow significantly due to the high volume of diagnostic procedures conducted in these settings.

Regional Insights

North America:

The region generated USD 0.68 billion in 2025 and is projected to reach USD 0.71 billion in 2026, maintaining its leading position due to strong healthcare infrastructure and high diagnostic adoption.

Europe:

Valued at USD 0.43 billion in 2025, the market is expected to grow to USD 0.45 billion in 2026, supported by government initiatives and adoption of advanced diagnostic technologies.

Asia Pacific:

The largest and fastest-growing region, with USD 0.78 billion in 2025, projected to reach USD 0.83 billion in 2026. High TB burden and improving healthcare infrastructure are key growth drivers.

Latin America & Middle East & Africa:

Latin America accounted for USD 0.24 billion in 2025, while the Middle East & Africa reached USD 0.28 billion, with steady growth expected due to increasing healthcare investments and market penetration by global players.

Competitive Landscape

The market is competitive, with key players such as F. Hoffmann-La Roche Ltd, bioMerieux SA, Abbott Laboratories, QIAGEN, Thermo Fisher Scientific Inc., and Cepheid (Danaher) leading the industry. These companies focus on product innovation, partnerships, and regulatory approvals to strengthen their market position.

Recent developments include:

  • September 2023: QIAGEN donated TB diagnostic kits to Malaysia's health ministry.
  • May 2022: Roche partnered with the Global Fund to enhance diagnostic infrastructure in developing regions.
  • September 2022: BD launched advanced molecular diagnostic systems for TB detection.

Conclusion

The global tuberculosis diagnostics market is expected to grow steadily from USD 2.40 billion in 2025 to USD 4.14 billion by 2034, driven by rising TB incidence, increasing government initiatives, and advancements in diagnostic technologies. While technical limitations and infrastructure challenges persist, the growing adoption of rapid molecular diagnostics and expanding healthcare investments in emerging economies will create strong growth opportunities. North America will continue to lead the market, while Asia Pacific is anticipated to emerge as the fastest-growing region, shaping the future of TB diagnostics globally.

Segmentation

By Type

  • Culture-based Diagnostics
  • Sputum Smear Microscopy
  • Rapid Molecular Diagnostics
  • Others

By End-user

  • Diagnostic Laboratories
  • Hospitals

By Region

  • North America (By Type, By End-user)
    • U.S.
    • Canada
  • Europe (By Type, By End-user)
    • U.K.
    • Germany
    • France
    • Italy
    • Russia
    • Nordic
    • Rest of Europe
  • Asia Pacific (By Type, By End-user)
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Type, By End-user)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, By End-user)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Key Industry Developments
  • 4.2. Incidence of Tuberculosis, By Key Countries
  • 4.3. Impact of COVID-19 on the Market

5. Global Tuberculosis (TB) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Culture-based Diagnostics
    • 5.1.2. Sputum Smear Microscopy
    • 5.1.3. Rapid Molecular Diagnostics
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By End-user
    • 5.2.1. Diagnostic Laboratories
    • 5.2.2. Hospitals
  • 5.3. Market Analysis, Insights and Forecast - By Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Tuberculosis (TB) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Culture-based Diagnostics
    • 6.1.2. Sputum Smear Microscopy
    • 6.1.3. Rapid Molecular Diagnostics
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By End-user
    • 6.2.1. Diagnostic Laboratories
    • 6.2.2. Hospitals
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Tuberculosis (TB) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Culture-based Diagnostics
    • 7.1.2. Sputum Smear Microscopy
    • 7.1.3. Rapid Molecular Diagnostics
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By End-user
    • 7.2.1. Diagnostic Laboratories
    • 7.2.2. Hospitals
  • 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Russia
    • 7.3.6. Nordic
    • 7.3.7. Rest of Europe

8. Asia Pacific Tuberculosis (TB) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Culture-based Diagnostics
    • 8.1.2. Sputum Smear Microscopy
    • 8.1.3. Rapid Molecular Diagnostics
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By End-user
    • 8.2.1. Diagnostic Laboratories
    • 8.2.2. Hospitals
  • 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. South Korea
    • 8.3.6. Southeast Asia
    • 8.3.7. Rest of Asia Pacific

9. Latin America Tuberculosis (TB) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Culture-based Diagnostics
    • 9.1.2. Sputum Smear Microscopy
    • 9.1.3. Rapid Molecular Diagnostics
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By End-user
    • 9.2.1. Diagnostic Laboratories
    • 9.2.2. Hospitals
  • 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Rest of Latin America

10. Middle East & Africa Tuberculosis (TB) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Culture-based Diagnostics
    • 10.1.2. Sputum Smear Microscopy
    • 10.1.3. Rapid Molecular Diagnostics
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By End-user
    • 10.2.1. Diagnostic Laboratories
    • 10.2.2. Hospitals
  • 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.3.1. GCC
    • 10.3.2. South Africa
    • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2026)
  • 11.2. Company Profiles
    • 11.2.1. F. Hoffmann-La Roche Ltd
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. bioMerieux SA
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. QIAGEN
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. BD
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Cepheid (Danaher)
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Thermo Fisher Scientific Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Abbott Laboratories
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Hologic, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Hain Lifescience GmbH
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Oxford Immunotec USA, Inc.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Tuberculosis (TB) Diagnostics Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 2: Global Tuberculosis (TB) Diagnostics Market Revenue (USD Billion) Forecast, by End-user, 2021-2034
  • Table 3: Global Tuberculosis (TB) Diagnostics Market Revenue (USD Billion) Forecast, by Region, 2021-2034
  • Table 4: North America Tuberculosis (TB) Diagnostics Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 5: North America Tuberculosis (TB) Diagnostics Market Revenue (USD Billion) Forecast, by End-user, 2021-2034
  • Table 6: North America Tuberculosis (TB) Diagnostics Market Revenue (USD Billion) Forecast, By Country, 2021-2034
  • Table 7: Europe Tuberculosis (TB) Diagnostics Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 8: Europe Tuberculosis (TB) Diagnostics Market Revenue (USD Billion) Forecast, by End-user, 2021-2034
  • Table 9: Europe Tuberculosis (TB) Diagnostics Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 10: Asia Pacific Tuberculosis (TB) Diagnostics Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 11: Asia Pacific Tuberculosis (TB) Diagnostics Market Revenue (USD Billion) Forecast, by End-user, 2021-2034
  • Table 12: Asia Pacific Tuberculosis (TB) Diagnostics Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Latin America Tuberculosis (TB) Diagnostics Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 14: Latin America Tuberculosis (TB) Diagnostics Market Revenue (USD Billion) Forecast, by End-user, 2021-2034
  • Table 15: Latin America Tuberculosis (TB) Diagnostics Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Middle East & Africa Tuberculosis (TB) Diagnostics Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 17: Middle East & Africa Tuberculosis (TB) Diagnostics Market Revenue (USD Billion) Forecast, by End-user, 2021-2034
  • Table 18: Middle East & Africa Tuberculosis (TB) Diagnostics Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Tuberculosis (TB) Diagnostics Market Revenue Breakdown (USD Billion, %) by Region, 2026 & 2034
  • Figure 2: Global Tuberculosis (TB) Diagnostics Market Value Share (%), by Type, 2026 & 2034
  • Figure 3: Global Tuberculosis (TB) Diagnostics Market Value Share (%), by End-user, 2026 & 2034
  • Figure 4: Global Tuberculosis (TB) Diagnostics Market Value (USD Billion), by Region, 2026 & 2034
  • Figure 5: North America Tuberculosis (TB) Diagnostics Market Value (USD Billion), by Type, 2026 & 2034
  • Figure 6: North America Tuberculosis (TB) Diagnostics Market Value Share (%), by Type, 2026
  • Figure 7: North America Tuberculosis (TB) Diagnostics Market Value (USD Billion), by End-user, 2026 & 2034
  • Figure 8: North America Tuberculosis (TB) Diagnostics Market Value Share (%), by End-user, 2026
  • Figure 9: North America Tuberculosis (TB) Diagnostics Market Value (USD Billion), By Country, 2026 & 2034
  • Figure 10: North America Tuberculosis (TB) Diagnostics Market Value Share (%), By Country, 2026
  • Figure 11: Europe Tuberculosis (TB) Diagnostics Market Value (USD Billion), by Type, 2026 & 2034
  • Figure 12: Europe Tuberculosis (TB) Diagnostics Market Value Share (%), by Type, 2026
  • Figure 13: Europe Tuberculosis (TB) Diagnostics Market Value (USD Billion), by End-user, 2026 & 2034
  • Figure 14: Europe Tuberculosis (TB) Diagnostics Market Value Share (%), by End-user, 2026
  • Figure 15: Europe Tuberculosis (TB) Diagnostics Market Value (USD Billion), By Country/ Sub-region, 2026 & 2034
  • Figure 16: Europe Tuberculosis (TB) Diagnostics Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 17: Asia Pacific Tuberculosis (TB) Diagnostics Market Value (USD Billion), by Type, 2026 & 2034
  • Figure 18: Asia Pacific Tuberculosis (TB) Diagnostics Market Value Share (%), by Type, 2026
  • Figure 19: Asia Pacific Tuberculosis (TB) Diagnostics Market Value (USD Billion), by End-user, 2026 & 2034
  • Figure 20: Asia Pacific Tuberculosis (TB) Diagnostics Market Value Share (%), by End-user, 2026
  • Figure 21: Asia Pacific Tuberculosis (TB) Diagnostics Market Value (USD Billion), By Country/ Sub-region, 2026 & 2034
  • Figure 22: Asia Pacific Tuberculosis (TB) Diagnostics Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 23: Latin America Tuberculosis (TB) Diagnostics Market Value (USD Billion), by Type, 2026 & 2034
  • Figure 24: Latin America Tuberculosis (TB) Diagnostics Market Value Share (%), by Type, 2026
  • Figure 25: Latin America Tuberculosis (TB) Diagnostics Market Value (USD Billion), by End-user, 2026 & 2034
  • Figure 26: Latin America Tuberculosis (TB) Diagnostics Market Value Share (%), by End-user, 2026
  • Figure 27: Latin America Tuberculosis (TB) Diagnostics Market Value (USD Billion), By Country/ Sub-region, 2026 & 2034
  • Figure 28: Latin America Tuberculosis (TB) Diagnostics Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 29: Middle East & Africa Tuberculosis (TB) Diagnostics Market Value (USD Billion), by Type, 2026 & 2034
  • Figure 30: Middle East & Africa Tuberculosis (TB) Diagnostics Market Value Share (%), by Type, 2026
  • Figure 31: Middle East & Africa Tuberculosis (TB) Diagnostics Market Value (USD Billion), by End-user, 2026 & 2034
  • Figure 32: Middle East & Africa Tuberculosis (TB) Diagnostics Market Value Share (%), by End-user, 2026
  • Figure 33: Middle East & Africa Tuberculosis (TB) Diagnostics Market Value (USD Billion), By Country/ Sub-region, 2026 & 2034
  • Figure 34: Middle East & Africa Tuberculosis (TB) Diagnostics Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 35: Global Tuberculosis (TB) Diagnostics Market Share (%), By Company, 2026